The FDA has extended its review deadline for Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment to July 23, 2026. This new form, if approved, would be the first anticancer drug administered via an on-body injector in the US. Meanwhile, the European Medicines Agency has given a positive opinion on Sarclisa SC, with a final EU decision expected soon. Sarclisa is already approved in nearly 60 countries and has treated over 60,000 patients worldwide, highlighting its significance in cancer care advancements.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
